New UK economic analyses show improved patient outcomes and health system savings – including nearly £200 million in projected UK NHS savings over 5 years – through increased uptake of home-based peritoneal dialysis compared to in-center hemodialysis
Zydus Hospitals Ahmedabad and Vadodara reach new heights in advanced transplant care AHMEDABAD, India, June 4, 2026 /PRNewswire/ -- Organ transplantation in India has come a...
MANILA, Philippines, Aug. 11, 2025 /PRNewswire/ -- AC Health, the healthcare arm of Ayala Corporation, has secured a landmark investment from ABC Impact, the...
MANILA, Philippines, Aug. 11, 2025 /PRNewswire/ -- AC Health, the healthcare arm of Ayala Corporation, has secured a landmark investment from ABC Impact, the...
MANILA, Philippines, Aug. 10, 2025 /PRNewswire/ -- AC Health, the healthcare arm of Ayala Corporation, has secured a landmark investment from ABC Impact, the...
NEW YORK, Aug. 09, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Unicycive Therapeutics, Inc. (“Unicycive” or the “Company”) (NASDAQ: UNCY). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.
SHANGHAI, Aug. 6, 2025 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on the discovery, clinical development, manufacturing,...
CANSCAN study enrolled 120 patients with chronic kidney disease using the investigational, semi-autonomous VxWave™ Ultrasound Imaging SystemThe VxWave Ultrasound Imaging System potentially provides important insights...
WALTHAM, Mass., July 28, 2025 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) today announced that the U.S. Food and Drug Administration (FDA) has approved EMPAVELI® (pegcetacoplan) as the first treatment for C3 glomerulopathy (C3G) or primary immune complex membranoproliferative glomerulonephritis (IC-MPGN) in patients 12 years of age and older, to reduce proteinuria. C3G and primary IC-MPGN are rare kidney diseases, affecting 5,000 people in the United States.1
Value-based kidney care leader expands capabilities in CHF care management, commercial self-insured populations, and AI-driven disease identification and payment integrity services
MCLEAN, Va., July 22,...
BIRMINGHAM, Ala. and CLEVELAND, Tenn., July 18, 2025 /PRNewswire/ -- Encompass Health Corp. (NYSE: EHC) today announced plans to build a freestanding, 40-bed inpatient rehabilitation...
The Vascular Access Devices Market Companies Quadrant delivers a thorough analysis of the global vascular access devices sector. Highlighting prominent players, innovations, and trends, it identifies the top 25 companies as quadrant leaders among over 100 evaluated. Vascular access devices (VADs), crucial for treatments like chemotherapy and dialysis, are set to grow from USD 5.99 billion in 2024 to USD 9.05 billion by 2030 at a 7.1% CAGR, fueled by rising demand and investments despite a skilled professional shortage. Key players include Beckton Dickinson, Teleflex, and ICU Medical, known for expanding portfolios through strategic acquisitions and innovations. The quadrant evaluates companies based on revenue, growth strategies, and product footprint across device types and applications.
The Vascular Access Devices Market Companies Quadrant delivers a thorough analysis of the global vascular access devices sector. Highlighting prominent players, innovations, and trends, it identifies the top 25 companies as quadrant leaders among over 100 evaluated. Vascular access devices (VADs), crucial for treatments like chemotherapy and dialysis, are set to grow from USD 5.99 billion in 2024 to USD 9.05 billion by 2030 at a 7.1% CAGR, fueled by rising demand and investments despite a skilled professional shortage. Key players include Beckton Dickinson, Teleflex, and ICU Medical, known for expanding portfolios through strategic acquisitions and innovations. The quadrant evaluates companies based on revenue, growth strategies, and product footprint across device types and applications.
The Medical Filtration Companies Quadrant offers a detailed analysis of the global medical filtration market, spotlighting key players, technological advancements, and market trends. This report categorizes the top 15 companies, including leaders like Merck KGaA, 3M, and Danaher, each excelling in areas such as healthcare and life sciences. Medical filtration is crucial for removing contaminants from fluids, ensuring safety and purity in applications like dialysis and drug delivery. Techniques include microfiltration and ultrafiltration, driven by chronic disease prevalence and regulatory standards. This innovation-rich market is essential for patient safety and product integrity in healthcare.
The Medical Filtration Companies Quadrant offers a detailed analysis of the global medical filtration market, spotlighting key players, technological advancements, and market trends. This report categorizes the top 15 companies, including leaders like Merck KGaA, 3M, and Danaher, each excelling in areas such as healthcare and life sciences. Medical filtration is crucial for removing contaminants from fluids, ensuring safety and purity in applications like dialysis and drug delivery. Techniques include microfiltration and ultrafiltration, driven by chronic disease prevalence and regulatory standards. This innovation-rich market is essential for patient safety and product integrity in healthcare.